{'fraction_non_alphanumeric': 0.0243161094224924, 'fraction_numerical': 0.00303951367781155, 'mean_word_length': 5.861111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Intracavitary administration of recombinant interferon in cancer patients with malignant effusions].

Interferon-beta (IFN-beta), 6 X 10 units/body, was administered intraperitoneally and intrapericardially daily to five recurrent cancer patients with malignant effusion. Two of them showed complete response with a disappearance of effusion and cytological negative. However, three patients showing a decrease in effusion and cytological negative were regarded as no change because of the short duration of the response (less than four weeks). Intracavitary administrations of IFN-beta were well tolerated, and no serious side effects were observed. Autopsies showed that all intestines with disseminated metastasis maintained organic elasticity and had neither ileus-like construction nor progressive adhesions. IFN-beta showed not only anticancer effects on malignant effusion, but protection against GI tract constriction through moderate control of the growth of connective tissue.